- Status:
- Topic prioritisation
- Technology type:
- Medicine
- Decision:
- Not selected
- Prioritisation programme:
- Medicines evaluation
- Rationale:
- The NICE-Wide Prioritisation Board met on 20 November 2025 and concluded that an evaluation would not be appropriate for this product. The 2024 voluntary scheme for branded medicines, pricing, access and growth states that NICE will continue to evaluate all new active substances and significant indications, except where there is a clear rationale not to do so. Decision makers concluded that the clear rationale to not evaluate this product is due to the existing NICE clinical guideline CG156 already recommending the use of gonadotrophins. Therefore, there would be no additional value in conducting a separate evaluation. Please see the eligibility criteria within the prioritisation manual for further information.
- ID number:
- 12290
Email enquiries
If you have any queries please email topic.selection@nice.org.uk
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 20 November 2025 | Prioritisation board meeting |
For further information on how we select topics for development, please see our page about topic prioritisation